首页> 外文期刊>Antiviral Research >Inhibition of HSV-1 replication and HSV DNA polymerase by the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid and its aglycone.
【24h】

Inhibition of HSV-1 replication and HSV DNA polymerase by the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid and its aglycone.

机译:氯氧喹啉核糖核苷6-氯-1,4-二氢-4-氧-1-(β-D-呋喃呋喃糖基)喹啉-3-羧酸及其糖苷配基对HSV-1复制和HSV DNA聚合酶的抑制作用。

获取原文
获取原文并翻译 | 示例
       

摘要

We describe in this paper that the synthetic chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid (compound A) and its free aglycogene base (compound B) inhibit, with low cytotoxicity, the replication of herpes simplex virus type 1 and 2 (HSV-1 and HSV-2). Compound A inhibited HSV-1 replication in Vero cells with an EC(50) of 1.3 and 1.4 microM for an acyclovir (ACV)-sensitive strain and an ACV-resistant strain of this virus, respectively. Additionally, it inhibited HSV-2 replication with an EC(50) of 1.1 microM. Compound B also inhibited the ACV-sensitive and -resistant HSV-1 strains, and HSV-2 at EC(50) values of 1.7, 1.9 and 1.6 microM, respectively. Time-of-addition assays, performed with compound A, suggested that this molecule at an early time point of the HSV replication cycle. Kinetic assays demonstrated that compounds A and B inhibit the HSV DNA polymerase activity in a noncompetitive fashion, with a K(i) equal to 0.1 and 0.2 microM,respectively. Taken together, our results suggest that compounds A and B represent promising lead molecules for further anti-HSV drug design.
机译:我们在本文中描述了合成的氯氧喹啉核糖核苷6-氯-1,4-二氢-4-氧代-1-(β-D-核呋喃糖基)喹啉-3-羧酸(化合物A)及其游离糖原碱(化合物B)以低细胞毒性抑制1型和2型单纯疱疹病毒(HSV-1和HSV-2)的复制。对于该病毒的阿昔洛韦(ACV)敏感株和ACV耐药株,化合物A抑制了Vero细胞中HSV-1复制,其EC(50)分别为1.3和1.4 microM。此外,它以1.1 microM的EC(50)抑制HSV-2复制。化合物B还在EC(50)值分别为1.7、1.9和1.6 microM时抑制了ACV敏感和耐药HSV-1株和HSV-2。用化合物A进行的添加时间测定表明该分子处于HSV复制周期的早期。动力学分析表明,化合物A和B以非竞争性方式抑制HSV DNA聚合酶活性,K(i)分别等于0.1和0.2 microM。两者合计,我们的结果表明,化合物A和B代表着有前途的铅分子,可用于进一步的抗HSV药物设计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号